Equities Analysts Set Expectations for KYMR FY2026 Earnings

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Investment analysts at Brookline Capital Markets cut their FY2026 earnings per share (EPS) estimates for shares of Kymera Therapeutics in a report issued on Thursday, October 29th. Brookline Capital Markets analyst L. Cann now expects that the company will post earnings of ($4.00) per share for the year, down from their prior estimate of ($3.97). Brookline Capital Markets currently has a “Buy” rating on the stock. The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($3.88) per share. Brookline Capital Markets also issued estimates for Kymera Therapeutics’ Q4 2026 earnings at ($1.34) EPS, FY2027 earnings at ($5.16) EPS, FY2028 earnings at ($6.07) EPS, FY2029 earnings at ($5.48) EPS and FY2030 earnings at ($5.84) EPS.

Other analysts have also recently issued reports about the stock. Wolfe Research raised shares of Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $180.00 target price on the stock in a report on Thursday, September 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Thursday, October 15th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Kymera Therapeutics in a research note on Thursday, July 30th. They set a “hold” rating and a $120.00 price objective on the stock. Loop Capital set a $132.00 target price on shares of Kymera Therapeutics in a report on Thursday, October 29th. Finally, Oppenheimer reissued an “outperform” rating and issued a $140.00 target price on shares of Kymera Therapeutics in a report on Thursday, October 29th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $139.16.

Kymera Therapeutics Price Performance

KYMR stock opened at $127.09 on Monday. Kymera Therapeutics has a 1-year low of $55.66 and a 1-year high of $133.88. The firm has a fifty day moving average price of $115.21 and a two-hundred day moving average price of $96.87. The firm has a market cap of $10.85 billion, a price-to-earnings ratio of -35.11 and a beta of 2.04.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, October 29th. The company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.26) by ($0.06). The firm had revenue of $1.35 million for the quarter, compared to the consensus estimate of $3.28 million. Kymera Therapeutics had a negative return on equity of 22.39% and a negative net margin of 285.33%. The business’s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter last year, the business earned ($0.94) earnings per share.

Insiders Place Their Bets

In other news, CEO Nello Mainolfi sold 30,000 shares of the company’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $113.80, for a total transaction of $3,414,000.00. Following the completion of the transaction, the chief executive officer owned 666,568 shares in the company, valued at approximately $75,855,438.40. This represents a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Brian Adams sold 6,371 shares of the stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $116.83, for a total transaction of $744,323.93. Following the completion of the sale, the insider directly owned 50,254 shares in the company, valued at approximately $5,871,174.82. This trade represents a 11.25% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 15.98% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of KYMR. BlackRock Inc. acquired a new position in Kymera Therapeutics during the 2nd quarter valued at about $635,067,000. Merck & Co. Inc. acquired a new stake in shares of Kymera Therapeutics in the 2nd quarter worth approximately $88,544,161. Jennison Associates LLC boosted its holdings in shares of Kymera Therapeutics by 2.5% in the first quarter. Jennison Associates LLC now owns 508,999 shares of the company’s stock valued at $42,395,000 after acquiring an additional 12,334 shares in the last quarter. Bank of America Corp DE bought a new position in shares of Kymera Therapeutics in the second quarter valued at approximately $43,378,000. Finally, Braidwell LP boosted its holdings in shares of Kymera Therapeutics by 12.0% in the second quarter. Braidwell LP now owns 378,163 shares of the company’s stock valued at $43,364,000 after acquiring an additional 40,604 shares in the last quarter.

Trending Headlines about Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Barclays raised its price target to $170 from $139 and reiterated an “Overweight” rating, implying substantial potential upside from the $127.09 reference price. Barclays price target update
• Positive Sentiment: BTIG initiated or reiterated a Buy view on Kymera, adding to the positive analyst tone. BTIG Buy rating
• Positive Sentiment: Truist Financial also reiterated its Buy rating, while another analyst raised its target to $116. Truist rating Raised price target
• Negative Sentiment: Kymera’s latest reported quarter missed consensus: loss per share was wider than expected and revenue came in below estimates. That weak financial update may temper the optimism around analyst upgrades. Q3 2026 results presentation
• Negative Sentiment: The $116 target, although raised, is below the reference share price of $127.09, signaling that analyst views are not uniformly bullish.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell’s natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities.

The company’s research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses.